Pixantrone maleate (BioDeep_00000859016)
代谢物信息卡片
化学式: C25H27N5O10 (557.1758)
中文名称: 吡咯烷酮二马来酸酯
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
InChI: 2*2-1-
描述信息
D000970 - Antineoplastic Agents > D059003 - Topoisomerase Inhibitors > D059005 - Topoisomerase II Inhibitors
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent
D004791 - Enzyme Inhibitors
同义名列表
2 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Ella Willenbacher, Karin Jöhrer, Wolfgang Willenbacher, Brigitte Flögel, Richard Greil, Brigitte Kircher. Pixantrone demonstrates significant in vitro activity against multiple myeloma and plasma cell leukemia.
Annals of hematology.
2019 Nov; 98(11):2569-2578. doi:
10.1007/s00277-019-03797-6. [PMID: 31628518] - Monica Longo, Paola Della Torre, Cecilia Allievi, Alberto Morisetti, Suliman Al-Fayoumi, Jack W Singer. Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin.
Reproductive toxicology (Elmsford, N.Y.).
2014 Jul; 46(?):20-30. doi:
10.1016/j.reprotox.2014.02.006. [PMID: 24602559] - Raushan T Kurmasheva, C Patrick Reynolds, Min H Kang, Cecilia Allievi, Peter J Houghton, Malcolm A Smith. Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.
Pediatric blood & cancer.
2014 May; 61(5):922-4. doi:
10.1002/pbc.24800. [PMID: 24166988] - P Borchmann, R Schnell, R Knippertz, J O Staak, G M Camboni, A Bernareggi, K Hübel, P Staib, A Schulz, V Diehl, A Engert. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2001 May; 12(5):661-7. doi:
10.1023/a:1011139016294. [PMID: 11432625] - S Faivre, E Raymond, V Boige, M Gatineau, X Buthaut, O Rixe, A Bernareggi, G Camboni, J P Armand. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2001 Jan; 7(1):43-50. doi:
. [PMID: 11205916] - L K Dawson, D I Jodrell, A Bowman, R Rye, B Byrne, A Bernareggi, G Camboni, J F Smyth. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.
European journal of cancer (Oxford, England : 1990).
2000 Dec; 36(18):2353-9. doi:
10.1016/s0959-8049(00)00342-7. [PMID: 11094309]
